Introduction to Limitations Of Current Risk Stratification System Models For Polycythemia Vera
Exploring Limitations Of Current Risk Stratification System Models For Polycythemia Vera reveals several interesting facts. Ghaith Abu-Zeinah, MD, Weill Cornell Medicine and the New York Presbyterian Hospital, New York City, NY, highlights the ...
Limitations Of Current Risk Stratification System Models For Polycythemia Vera Comprehensive Overview
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into treatment ... Jamile M. Shammo, MD, provides insight on the For more resources and information regarding anticancer targeted therapies:
Summary & Highlights for Limitations Of Current Risk Stratification System Models For Polycythemia Vera
- This video is part of the HMP Education content archive and may include previously accredited educational material. While this ...
- Richard Silver, MD, Weill Cornell Medical College, New York, NY, comments on the efficacy of interferon (IFN) in comparison to ...
- Join Drs Tania Jain and Pankit Vachhani as they discuss the nuance involved in the
- Yelena Ginzburg, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, discusses the efficacy and side effects ...
Stay tuned for more updates related to Limitations Of Current Risk Stratification System Models For Polycythemia Vera.
